SPONSORED CONTENT
Uncertainty has become a constant in the 340B landscape. Legal challenges, shifting manufacturer policies, and evolving oversight have made one thing clear: waiting for definitive answers before taking action is no longer a viable strategy.
For covered
Q: What is the primary problem 340B Referral Compass solves?
Referral Compass helps covered entities (CEs) address one of the most difficult and often underdeveloped areas…
Read More »SPONSORED CONTENT
There has been no formal announcement explaining how the Inflation Reduction Act (IRA) is playing out operationally within 340B.
Instead, it’s showing up in the data. For many organizations, it looks subtle at first. A dip in qualified claims.
…SPONSORED CONTENT
Q1 2026 started rougher than predicted for 340B programs. Ceiling prices compressed. Penny pricing disappeared on drugs that used to be your biggest savings. And an entire drug category that looked like a growth engine 12 months ago went
…
Q: What is the primary problem Pillr One solves?
340B programs are increasingly difficult to manage across fragmented systems that handle mixed-use, central distribution, contract…
Read More »
Q: Where did you grow up?
South Alabama
Q: Tell us about your educational background and training.
I graduated from Auburn University’s Harrison School of Pharmacy. My career as a pharmacist includes retail, hospital, and specialty pharmacy.
Q: What are your favorites?
Food: Mexican, chocolate
Movie: I do not watch many movies, but
…
SPONSORED CONTENT
TIP: Regularly review your 340B ESP configuration to ensure alignment across TPA & wholesaler systems, because even small inconsistencies can quietly escalate into significant missed savings opportunities.
Q: What is the primary problem RxParadigm’s Tungsten+PLUS™ solves?
Tungsten+PLUS™ is a transparent platform designed to eliminate 340B duplicate discounts, reconcile Inflation Reduction Act (IRA)-driven…
Read More »SPONSORED CONTENT
State-level oversight of the 340B Drug Pricing Program continues to expand. In 2025 alone, states including Colorado, Hawaii, Idaho, Indiana, Ohio, Rhode Island, and Vermont enacted laws requiring covered entities to report acquisition costs, reimbursement, and the use of 340B
…SPONSORED CONTENT
340B teams are facing ever-rising expectations and workloads. Programs must juggle core operational responsibilities while continuously adapting to evolving policies and regulatory changes (especially as we’ve experienced
…
